Personalized medicine gained a national platform with the January 2015 proposal by President Barack Obama to analyze genetic information from more than 1 million American volunteers, as part of a new initiative to understand human disease and develop medicines targeted to an individual’s genetic makeup. The president included a $215-million line item in his proposed 2016 budget to fund this initiative.
Dr. Bosserman explains that more and more private practices are being absorbed into hospitals, academic medical centers, and health systems. This could pave the way for more integrated care for oncology patients and provide them with a clear way to compare outcomes, survival rates, and costs.
According to Dr. Bosserman, a high-quality breast cancer program takes into consideration all of a patient's needs from day 1 through to survivorship. Factors such as early diagnosis and treatment, navigation, care coordination, and survivorship plans must all be part of the process.
Prostate cancer is the most common noncutaneous cancer in men and the second most common cause of cancer-related death.1 Normal prostate cells and prostate cancer cells require the presence of androgen for growth and survival. In advanced prostate cancer, androgen deprivation therapy (ADT), medically or surgically, has been the mainstay.
San Francisco, CA—The rising costs of biomolecular testing and targeted drugs have prompted many to ask whether the United States can afford personalized medicine in oncology. At the Third Annual PMO Live Conference, a Global Biomarkers Consortium Initiative, medical directors from 2 health plans tackled this question from the payer perspective.
Results 1 - 6 of 6